ERBB2 and breast cancer: The successful design and demonstration of such a clinically-promising, ultrasmall nanoimmunoconjugate for detection of HER2-expressing breast cancers serves as the foundation for staging, risk stratification, treatment planning, and next-stage targeted therapeutic developments.